Cell Source, Inc. announced that Dr. Steven Burakoff, Director of the Tisch Cancer Institute at Mount Sinai Medical Center and Professor of Cancer Medicine and Hematology and Medical Oncology at the Icahn School of Medicine at Mount Sinai, has joined its Scientific Advisory Board. Dr. Burakoff was Chair of Pediatric Oncology and served on the Executive Committee of the Board of Trustees at the Dana Farber Cancer Institute, Chaired the Advisory Committee on Immunology and Immunotherapy of the American Cancer Society. Dr. Burakoff has served as a consultant to Novartis, Bristol Myers Squibb and Hoffman Laroche and was on the Board of Directors of Genzyme Corporation when it was acquired by Sanofi-Aventis in 2011.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0008 USD | +300.00% | +300.00% | -99.83% |
1st Jan change | Capi. | |
---|---|---|
-99.83% | 32.82K | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- CLCS Stock
- News Cell Source, Inc.
- Dr. Steven Burakoff Joins Cell Source, Inc.'s Scientific Advisory Board